These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 30570436)

  • 1. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
    Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
    Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
    Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
    Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
    Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
    Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
    Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij HB; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
    Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
    Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
    J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implication of serum biomarkers and patient age in inflammatory demyelinating diseases.
    Lee EJ; Lim YM; Kim S; Choi L; Kim H; Kim K; Kim HW; Lee JS; Kim KK
    Ann Clin Transl Neurol; 2020 Jun; 7(6):992-1001. PubMed ID: 32495489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis.
    Robinson T; Abdelhak A; Bose T; Meinl E; Otto M; Zettl UK; Dersch R; Tumani H; Rauer S; Huss A
    Cells; 2020 Nov; 9(12):. PubMed ID: 33255854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma glial fibrillary acidic protein and neurofilament light chain in relation to disability worsening in multiple sclerosis.
    Pauwels A; Van Schependom J; Devolder L; Van Remoortel A; Nagels G; Bjerke M; D'hooghe MB
    Mult Scler; 2022 Oct; 28(11):1685-1696. PubMed ID: 36059263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.
    van Ballegoij WJC; van de Stadt SIW; Huffnagel IC; Kemp S; Willemse EAJ; Teunissen CE; Engelen M
    Ann Clin Transl Neurol; 2020 Nov; 7(11):2127-2136. PubMed ID: 33047897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NfL and GFAP in serum are associated with microstructural brain damage in progressive multiple sclerosis.
    Ammitzbøll C; Dyrby TB; Börnsen L; Schreiber K; Ratzer R; Romme Christensen J; Iversen P; Magyari M; Lundell H; Jensen PEH; Sørensen PS; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Sep; 77():104854. PubMed ID: 37418931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
    Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
    J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum GFAP and NfL levels in benign relapsing-remitting multiple sclerosis.
    Niiranen M; Kontkanen A; Jääskeläinen O; Tertsunen HM; Selander T; Hartikainen P; Huber N; Solje E; Haapasalo A; Kokkola T; Lohioja T; Herukka SK; Simula S; Remes AM
    Mult Scler Relat Disord; 2021 Nov; 56():103280. PubMed ID: 34627002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
    Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
    Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain-derived neurotrophic factor, neurofilament light and glial fibrillary acidic protein do not change in response to aerobic training in people with MS-related fatigue - a secondary analysis of a randomized controlled trial.
    Gravesteijn AS; Beckerman H; Willemse EA; Hulst HE; de Jong BA; Teunissen CE; de Groot V
    Mult Scler Relat Disord; 2023 Feb; 70():104489. PubMed ID: 36621163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling serum neurofilament light chain and glial fibrillary acidic protein in primary progressive multiple sclerosis.
    Giarraputo J; Giamberardino S; Arvai S; Maichle S; Eckstein C; Newby LK; Gregory S
    J Neuroimmunol; 2021 May; 354():577541. PubMed ID: 33725477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of serum neurofilament light chain and glial fibrillary acidic protein levels with cognitive decline in Parkinson's disease.
    Mao S; Teng X; Li Z; Zu J; Zhang T; Xu C; Cui G
    Brain Res; 2023 Apr; 1805():148271. PubMed ID: 36754139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis.
    Lee HL; Seok JM; Chung YH; Min JH; Baek SH; Kim SM; Sohn E; Kim J; Kang SY; Hong YH; Shin HY; Cho JY; Oh J; Lee SS; Kim S; Kim SH; Kim HJ; Kim BJ; Kim BJ
    Mult Scler Relat Disord; 2023 Nov; 79():104957. PubMed ID: 37688927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.